Enanta Pharmaceuticals (ENTA) Other Non-Current Liabilities (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted Other Non-Current Liabilities of $278000.0 for Q1 2026, down 99.73% on a QoQ basis from $102.8 million in Q4 2025, and up 14.4% year-over-year from $243000.0 in Q1 2025.
Enanta Pharmaceuticals (ENTA) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $278000.0 for Q1 2026.
- Quarterly Other Non-Current Liabilities rose 14.4% year-over-year to $278000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $278000.0 (up 14.4% YoY) and the FY2025 annual result came in at $260000.0, up 12.55% from the prior year.
- Other Non-Current Liabilities was $278000.0 for Q1 2026 at Enanta Pharmaceuticals, down from $102.8 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $165.0 million in Q2 2023 and bottomed at $227000.0 in Q2 2024.
- A 5-year average of $43.7 million and a median of $411000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities sank 99.86% — and 2025, when it surged 52738.33%.
- Enanta Pharmaceuticals' Other Non-Current Liabilities stood at $414000.0 in 2022, then jumped by 56.76% to $649000.0 in 2023, then tumbled by 63.79% to $235000.0 in 2024, then jumped by 43654.04% to $102.8 million in 2025, then plunged by 99.73% to $278000.0 in 2026.
- Business Quant data shows ENTA's Other Non-Current Liabilities at $278000.0 in Q1 2026, $102.8 million in Q4 2025, and $260000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Enanta Pharmaceuticals | 376.07 Mn | 212.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 278,000.00 |
| Dec 31, 2025 | 102.82 Mn |
| Sep 30, 2025 | 260,000.00 |
| Jun 30, 2025 | 119.94 Mn |
| Mar 31, 2025 | 243,000.00 |
| Dec 31, 2024 | 235,000.00 |
| Sep 30, 2024 | 231,000.00 |
| Jun 30, 2024 | 227,000.00 |
| Mar 31, 2024 | 147.78 Mn |
| Dec 31, 2023 | 649,000.00 |
| Sep 30, 2023 | 159.43 Mn |
| Jun 30, 2023 | 164.98 Mn |
| Mar 31, 2023 | 408,000.00 |
| Dec 31, 2022 | 414,000.00 |
| Jun 30, 2022 | 354,000.00 |
| Mar 31, 2022 | 876,000.00 |
| Dec 31, 2021 | 856,000.00 |
| Sep 30, 2021 | 558,000.00 |
| Jun 30, 2021 | 317,000.00 |
| Mar 31, 2021 | 686,000.00 |